osimertinib
Showing 1 - 25 of 113
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in
Not yet recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Cetuximab
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 2, 2023
NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)
Not yet recruiting
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Osimertinib
- Aspirin
- (no location specified)
Aug 27, 2023
NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Telisotuzumab Vedotin
- +4 more
- (no location specified)
Oct 17, 2023
Colorectal Cancer, NSCLC Trial (GDC-1971, Osimertinib, Cetuximab)
Not yet recruiting
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- GDC-1971
- +2 more
- (no location specified)
Jul 12, 2023
NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Osimertinib
- Amivantamab
- (no location specified)
Mar 24, 2023
NSCLC, Stage I Trial in Tianjin (Osimertinib)
Recruiting
- NSCLC, Stage I
- Osimertinib
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Jan 6, 2023
Cancer Trial (Osimertinib)
Not yet recruiting
- Cancer
- Osimertinib
- (no location specified)
Nov 17, 2022
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Duarte, New Haven (procedure, drug, radiation, other)
Not yet recruiting
- Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Biospecimen Collection
- +5 more
-
Duarte, California
- +1 more
Aug 24, 2023
Non Small Cell Lung Cancer Trial in Italy (Osimertinib)
Recruiting
- Non Small Cell Lung Cancer
- Osimertinib
-
Ancona, Italy
- +10 more
Mar 14, 2023
Non Small Cell Lung Cancer, Lung Cancer Trial in Los Angeles (Osimertinib, Carotuximab)
Recruiting
- Non Small Cell Lung Cancer
- Lung Cancer
- Osimertinib
- Carotuximab
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Dec 20, 2022
NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Patritumab deruxtecan
- Osimertinib
-
Santa Monica, California
- +13 more
Feb 1, 2023
Lung Adenocarcinoma, Lung Tumors Trial run by the NCI (osimertinib, LAT)
Completed
- Lung Adenocarcinoma
- Lung Neoplasms
- osimertinib
- LAT
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 17, 2022
NSCLC, EGFR Activating Mutation Trial in Changsha, Shanghai (TY-9591, Osimertinib, Osimertinib)
Recruiting
- NSCLC
- EGFR Activating Mutation
- TY-9591
- +3 more
-
Changsha, Hunan, China
- +1 more
Dec 6, 2022
NSCLC Trial in Boston (Osimertinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Osimertinib
-
Boston, Massachusetts
- +1 more
Sep 28, 2022
Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)
Recruiting
- Lung Cancer Metastatic
- EGFR Gene Mutation
- Osimertinib
- Alisertib
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 10, 2022
NSCLC, NSCLC Trial in Miami, Cleveland (Osimertinib)
Active, not recruiting
- NSCLC
- Non-small Cell Lung Cancer
- Osimertinib
-
Miami, Florida
- +1 more
Nov 8, 2022
NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)
Terminated
- Carcinoma, Non-Small-Cell Lung
- capmatinib
- +4 more
-
Kashiwa, Chiba, Japan
- +3 more
Jan 31, 2023
NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)
Terminated
- Carcinoma, Non-Small-Cell Lung
- Trastuzumab emtansine
- Osimertinib
-
Maastricht, Limburg, Netherlands
- +4 more
Nov 7, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Trial in Houston
Active, not recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +4 more
- Alisertib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 31, 2022
NSCLC Trial in China (Osimertinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- Osimertinib
-
Beijing, China
- +3 more
Sep 15, 2022
EGFR T790M, Osimertinib, NSCLC Trial in Beijing (Osimertinib)
Recruiting
- EGFR T790M
- +3 more
- Osimertinib
-
Beijing, Beijing, ChinaJunling Li
Jul 21, 2022
Osimertinib for NSCLC With Uncommon EGFR Mutations
Enrolling by invitation
- Carcinoma, Non-Small-Cell Lung
- Genes, erbB-1
- Osimertinib
-
Ramat Gan, IsraelSheba Medical Centre
Jun 14, 2022
NSCLC, EGFR Positive NSCLC, Oligoprogression Trial in München (Osimertinib, Radiotherapy)
Recruiting
- NSCLC
- +2 more
- Osimertinib
- Radiotherapy
-
München, GermanyLMU Klinikum der Universität München
May 17, 2022